Cantor Fitzgerald Begins Coverage on Trulieve Cannabis (NYSE:TRLV)

Equities research analysts at Cantor Fitzgerald started coverage on shares of Trulieve Cannabis (NYSE:TRLV) in a research note issued to investors on Monday, MarketBeat.com reports. The firm set an “overweight” rating and a $15.00 price target on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 69.78% from the stock’s current price.

A number of other analysts also recently weighed in on the stock. Zacks Research raised shares of Trulieve Cannabis to a “hold” rating in a report on Thursday, June 18th. Wall Street Zen cut shares of Trulieve Cannabis from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings initiated coverage on shares of Trulieve Cannabis in a research note on Tuesday, June 16th. They issued a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $15.00.

Trulieve Cannabis Price Performance

Shares of Trulieve Cannabis stock opened at $8.84 on Monday. Trulieve Cannabis has a 12-month low of $4.19 and a 12-month high of $13.28.

Insiders Place Their Bets

In other Trulieve Cannabis news, CEO Kim A. Rivers sold 136,811 shares of Trulieve Cannabis stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $8.76, for a total value of $1,198,464.36. Following the transaction, the chief executive officer owned 1,476,913 shares in the company, valued at $12,937,757.88. The trade was a 8.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,699,007 shares of company stock valued at $14,661,355 over the last quarter. Company insiders own 3.79% of the company’s stock.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.